339 related articles for article (PubMed ID: 29974551)
1. Power morcellation-induced dissemination of sarcomatous component arising in leiomyoma.
Emoto I; Moriuchi K; Kanbayashi S; Inohaya A; Ri Y; Sato Y
J Obstet Gynaecol Res; 2018 Sep; 44(9):1843-1849. PubMed ID: 29974551
[TBL] [Abstract][Full Text] [Related]
2. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.
Zullo F; Venturella R; Raffone A; Saccone G
Cochrane Database Syst Rev; 2020 May; 5(5):CD013352. PubMed ID: 32374421
[TBL] [Abstract][Full Text] [Related]
3. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(3):410-4. PubMed ID: 25460521
[TBL] [Abstract][Full Text] [Related]
4. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
5. Iatrogenic parasitic leiomyoma and leiomyomatosis peritonealis disseminata following uterine morcellation.
Lu B; Xu J; Pan Z
J Obstet Gynaecol Res; 2016 Aug; 42(8):990-9. PubMed ID: 27125448
[TBL] [Abstract][Full Text] [Related]
6. Long-term sequelae of unconfined morcellation during laparoscopic gynecological surgery.
Cohen A; Tulandi T
Maturitas; 2017 Mar; 97():1-5. PubMed ID: 28159054
[TBL] [Abstract][Full Text] [Related]
7. ACOG Committee Opinion No. 770: Uterine Morcellation for Presumed Leiomyomas.
Obstet Gynecol; 2019 Mar; 133(3):e238-e248. PubMed ID: 30801477
[TBL] [Abstract][Full Text] [Related]
8. Electric morcellation-related reoperations after laparoscopic myomectomy and nonmyomectomy procedures.
Pereira N; Buchanan TR; Wishall KM; Kim SH; Grias I; Richard SD; Della Badia CR
J Minim Invasive Gynecol; 2015 Feb; 22(2):163-76. PubMed ID: 25218993
[TBL] [Abstract][Full Text] [Related]
9. Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822.
Obstet Gynecol; 2021 Mar; 137(3):e63-e74. PubMed ID: 33595252
[TBL] [Abstract][Full Text] [Related]
10. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
11. A medical-legal review of power morcellation in the face of the recent FDA warning and litigation.
Ton R; Kilic GS; Phelps JY
J Minim Invasive Gynecol; 2015; 22(4):564-72. PubMed ID: 25623369
[TBL] [Abstract][Full Text] [Related]
12. Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A; Farghaly SA
Minerva Ginecol; 2018 Feb; 70(1):84-88. PubMed ID: 28975775
[TBL] [Abstract][Full Text] [Related]
13. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
14. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker WH; Kaunitz AM; Pritts EA; Olive DL; Chalas E; Clarke-Pearson DL; Berek JS;
Obstet Gynecol; 2016 Jan; 127(1):18-22. PubMed ID: 26646134
[TBL] [Abstract][Full Text] [Related]
15. Nonmalignant Sequelae of Unconfined Morcellation at Laparoscopic Hysterectomy or Myomectomy.
Tulandi T; Leung A; Jan N
J Minim Invasive Gynecol; 2016; 23(3):331-7. PubMed ID: 26802909
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of occult leiomyosarcomas and atypical leiomyomas after laparoscopic morcellation of leiomyomas in reproductive-age women.
Pados G; Tsolakidis D; Theodoulidis V; Makedos A; Zaramboukas T; Tarlatzis B
Hum Reprod; 2017 Oct; 32(10):2036-2041. PubMed ID: 28938732
[TBL] [Abstract][Full Text] [Related]
17. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.
Harris JA; Swenson CW; Uppal S; Kamdar N; Mahnert N; As-Sanie S; Morgan DM
Am J Obstet Gynecol; 2016 Jan; 214(1):98.e1-98.e13. PubMed ID: 26314519
[TBL] [Abstract][Full Text] [Related]
18. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread.
Zapardiel I; Boria F; Halaska MJ; De Santiago J
J Minim Invasive Gynecol; 2021 Aug; 28(8):1442-1443. PubMed ID: 32961359
[TBL] [Abstract][Full Text] [Related]
20. Minilaparotomy Versus Laparoscopic Myomectomy After Cessation of Power Morcellation: Rate of Wound Complications.
Dubin AK; Wei J; Sullivan S; Udaltsova N; Zaritsky E; Yamamoto MP
J Minim Invasive Gynecol; 2017; 24(6):946-953. PubMed ID: 28552622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
